Risk.net

Lyxor AM launches two new ETFs in Amsterdam

Lyxor Asset Management has listed two new exchange-traded funds (ETFs) on Euronext Amsterdam. The funds have been built on versions of the reference index for the exchange: the Amsterdam Exchange Index (AEX), which tracks 23 of the stocks that trade on Euronext Amsterdam. Two versions of the equity indexes have been specifically designed to be used as an underlying for ETFs, and are both calculated and published by NYSE Euronext.

    • Sophia Morrell
  • LinkedIn  
  • Save this article
  • Print this page  

The Lyxor ETF AEX Short offers inverse exposure to the performance of the AEX Total Return Index. The second fund, the Lyxor ETF AEX Leverage, is linked to a leveraged version of the AEX, which exposes investors to 200% of the AEX's movements. Both funds are denominated in euros.

Related stories:

Casam unveils 10 ETFs on Euronext Paris

Investors opt for ETFs to provide transparency and liquidity

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Copyright Infopro Digital Limited. All rights reserved.

You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@risk.net

Copyright Infopro Digital Limited. All rights reserved.

You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@risk.net

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

More on Structured products

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here